Will Single-Time Tumor Profiling and a “Guilt by Association” Approach Allow Us to Outsmart HER2-Positive Breast Cancer?

Abstract

Amplification of the HER2/Neu ( ERBB2 ) gene, the second member of the epidermal growth factor receptor (ErbB) tyrosine kinase family, occurs in ∼25% of invasive breast cancers and is associated with poor patient outcome ([1][1]). Trastuzumab (Herceptin), a humanized monoclonal IgG1 that binds to